ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1503

The Prevalence of Axial Spondyloarthritis in Israel

Sara Borok Lev-Ran1, Hagit Sarvagyl-Maman2, Victoria Furer3, Sara Pel4, Iddo Drukman5, Gideon Flusser5 and Ori Elkayam6, 1Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, 2Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, 3Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 4Rheumatology, Sourasky Medical Center, Tel Aviv, Israel, 5Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, 6Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: axial spondyloarthritis, internet, seronegative spondyloarthropathy and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%, the exact prevalence of axial SpA in the general population is unknown. To evaluate the prevalence of axial SpA according to the ASAS classification criteria among the Israeli population of Jewish origin.

Methods: The study composed of 3 steps: 1) preliminary screening of the general population based on an internet screening survey of 4000 Israelis of Jewish origin, aged 18-45, which form a representative sample of the general population. Those answering positively to the question of suffering from lower back pain (LBP) for more than 3 months continued to the second step questionnaire. 2) step 2 comprised of 11 questions pertaining to inflammatory back pain (IBP) and other SpA features such as arthritis, enthesitis, uveitis, dactylitis, psoriasis, Crohn’s disease or colitis, and family history of SpA. Those who answered positively to at least one of the questions were invited to undergo further evaluation by a rheumatologist. Those who agreed moved to the 3rd step and were invited to the department of rheumatology. 3) the evaluation included a clinical form comprising the SpA features as specified in the ASAS criteria, imaging (X-RAY and MRI of the sacroiliac joints) and laboratory evaluation (CRP and HLA-B27).

Results: A total of 4012 people were screened via the internet survey. Of these, 1440 (36%) suffered from LBP for more than 3 months. 467 fulfilled the ASAS criteria for inflammatory back pain (32%) while 30-60% described at least one characteristic of inflammatory back pain, 11% arthralgia/arthritis, 12% dactylitis and 13% enthesitis. Four percent reported uveitis, 3.5% on psoriasis and 2% on Crohn’s disease or colitis. 1389 (35%) of them continued to step 2 and 981 (70%) answered positively to at least one of the SpA feature questions and were invited to be examined by a rheumatologist. 417 agreed and 60 kept their appointment. 3 patients were further excluded based on the exclusion criteria. HLA-B27 returned negative in all but one patient. The MRI showed findings compatible with sacroiliitis in 20 patients (active and/or chronic). Fifteen patients complied with the ASAS classification criteria for axial SpA resulting in an estimated prevalence of at least 0.4%.

Conclusion: The estimated prevalence of axial SpA is at least 0.4%. Taking into consideration the proportion of patients with IBP (6%), the prevalence is probably much higher and is between 0.4 and at least 1%. Internet screening for IBP may be a useful tool for detection of axial SpA.


Disclosure: S. Borok Lev-Ran, None; H. Sarvagyl-Maman, None; V. Furer, None; S. Pel, None; I. Drukman, None; G. Flusser, None; O. Elkayam, None.

To cite this abstract in AMA style:

Borok Lev-Ran S, Sarvagyl-Maman H, Furer V, Pel S, Drukman I, Flusser G, Elkayam O. The Prevalence of Axial Spondyloarthritis in Israel [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-axial-spondyloarthritis-in-israel/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-axial-spondyloarthritis-in-israel/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology